

Dennis M Black

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/152383/publications.pdf>

Version: 2024-02-01

168
papers

34,687
citations

6254

80
h-index

4991

167
g-index

170
all docs

170
docs citations

170
times ranked

15586
citing authors

#	ARTICLE	IF	CITATIONS
1	Bisphosphonates and the risk of atypical femur fractures. <i>Bone</i> , 2022, 156, 116297.	2.9	17
2	Low cumulative disease activity is associated with higher bone mineral density in a majority Latinx and Asian US rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151972.	3.4	11
3	Prebiotic to Improve Calcium Absorption in Postmenopausal Women After Gastric Bypass: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1053-1064.	3.6	4
4	A Prospective Open-Label Observational Study of a Buffered Soluble 70-mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study. <i>JBMR Plus</i> , 2021, 5, e10510.	2.7	7
5	A novel effervescent formulation of oral weekly alendronate (70mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2529-2537.	2.9	5
6	Outcomes post fragility fracture among members of an integrated healthcare organization. <i>Osteoporosis International</i> , 2021, , 1.	3.1	5
7	Non-contrast cardiac CT-based quantitative evaluation of epicardial and intra-thoracic fat in healthy, recently menopausal women: Reproducibility data from the Kronos Early Estrogen Prevention Study. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 55-59.	1.3	7
8	Increases in PYY and uncoupling of bone turnover are associated with loss of bone mass after gastric bypass surgery. <i>Bone</i> , 2020, 131, 115115.	2.9	17
9	Now That You Can Get What You Want, Can You Keep What You Need?. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 217-218.	2.8	0
10	Bone mineral density as a surrogate biomarker for fracture risk reduction – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 876.	11.4	1
11	Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 672-682.	11.4	117
12	Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2363-2371.	2.8	24
13	Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. <i>New England Journal of Medicine</i> , 2020, 383, 743-753.	27.0	201
14	Zoledronate. <i>Bone</i> , 2020, 137, 115390.	2.9	39
15	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 236-243.	2.8	15
16	Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 29-35.	2.8	23
17	The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 21-28.	2.8	12
18	History of alendronate. <i>Bone</i> , 2020, 137, 115411.	2.9	30

#	ARTICLE	IF	CITATIONS
19	A Perspective on Postmenopausal Bone Loss with Aging. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 171-172.	2.8	2
20	Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1977-1978.	2.8	2
21	Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 632-642.	2.8	197
22	Effect of Insulin Resistance on BMD and Fracture Risk in Older Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3303-3310.	3.6	58
23	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1595-1622.	3.6	470
24	Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. <i>Endocrine Reviews</i> , 2019, 40, 333-368.	20.1	136
25	The Kronos Early Estrogen Prevention Study (KEEPS). <i>Menopause</i> , 2019, 26, 1071-1084.	2.0	97
26	Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 810-816.	2.8	22
27	Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1291-1301.	2.8	77
28	Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial. <i>Journal of Pediatrics</i> , 2018, 198, 201-208.e3.	1.8	14
29	Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly Impact Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 975-986.	2.8	71
30	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 634-642.	2.8	51
31	The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 389-395.	2.8	68
32	Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 63-69.	2.8	61
33	Reply to: Indications of Increased Vertebral Fracture Risk in Patients With Type 2 Diabetes. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 183-183.	2.8	2
34	The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. <i>Journal of Pediatrics</i> , 2017, 183, 19-25.e2.	1.8	25
35	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 200-210.	3.0	109
36	Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause. <i>JAMA Internal Medicine</i> , 2017, 177, 1471.	5.1	59

#	ARTICLE	IF	CITATIONS
37	Bone Marrow Fat Changes After Gastric Bypass Surgery Are Associated With Loss of Bone Mass. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2239-2247.	2.8	59
38	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10.	2.8	127
39	Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 17-23.	2.8	75
40	Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 495.	2.6	4
41	Osteoporosis and Bone Biology. , 2016, , 1323-1364.		7
42	Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1767-1773.	2.8	24
43	Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. <i>Drugs and Aging</i> , 2016, 33, 347-353.	2.7	30
44	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. <i>Physiological Genomics</i> , 2016, 48, 33-41.	2.3	23
45	Degree of Trauma Differs for Major Osteoporotic Fracture Events in Older Men Versus Older Women. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 204-207.	2.8	23
46	Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns. <i>Journal of Pediatrics</i> , 2016, 177, 97-102.e2.	1.8	65
47	Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 396.	1.9	23
48	Overlapping Surgery in the Ambulatory Orthopaedic Setting. <i>Journal of Bone and Joint Surgery - Series A</i> , 2016, 98, 1859-1867.	3.0	62
49	What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1500-1503.	2.8	44
50	Association of 3D Geometric Measures Derived From Quantitative Computed Tomography With Hip Fracture Risk in Older Men. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1550-1558.	2.8	17
51	Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2016, 374, 254-262.	27.0	1,101
52	Vitamin D Supplementation and Increased Risk of Falling. <i>JAMA Internal Medicine</i> , 2016, 176, 171.	5.1	27
53	Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. <i>Journal of Pediatrics</i> , 2016, 168, 23-29.e4.	1.8	68
54	Predicting Hip Fracture Type With Cortical Bone Mapping (CBM) in the Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2067-2077.	2.8	48

#	ARTICLE	IF	CITATIONS
55	Association between femur size and a focal defect of the superior femoral neck. <i>Bone</i> , 2015, 81, 60-66.	2.9	9
56	Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1377-1385.	2.8	131
57	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPSâ€“Cognitive and Affective Study. <i>PLoS Medicine</i> , 2015, 12, e1001833.	8.4	330
58	The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015, 30, 934-944.	2.8	205
59	Abdominal aortic calcification and risk of fracture among older women â€” The SOF study. <i>Bone</i> , 2015, 81, 16-23.	2.9	26
60	Inhaled Nitric Oxide Increases Urinary Nitric Oxide Metabolites and Cyclic Guanosine Monophosphate in Premature Infants: Relationship to Pulmonary Outcome. <i>American Journal of Perinatology</i> , 2015, 32, 225-232.	1.4	12
61	Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 570-574.	2.8	21
62	The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 331-341.	2.6	25
63	Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4546-4554.	3.6	109
64	High hip fracture risk in men with severe aortic calcification: MrOS study. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 968-975.	2.8	38
65	Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy. <i>JAMA Internal Medicine</i> , 2014, 174, 1126.	5.1	116
66	Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1550.	5.1	51
67	Prediction Models of Prevalent Radiographic Vertebral Fractures Among Older Men. <i>Journal of Clinical Densitometry</i> , 2014, 17, 449-457.	1.2	19
68	A Model of BMD Changes After Alendronate Discontinuation to Guide Postalendronate BMD Monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4094-4100.	3.6	10
69	Fracture risk in diabetic elderly men: the MrOS study. <i>Diabetologia</i> , 2014, 57, 2057-2065.	6.3	215
70	Prediction Models of Prevalent Radiographic Vertebral Fractures Among Older Women. <i>Journal of Clinical Densitometry</i> , 2014, 17, 378-385.	1.2	19
71	Arterial Imaging Outcomes and Cardiovascular Risk Factors in Recently Menopausal Women. <i>Annals of Internal Medicine</i> , 2014, 161, 249.	3.9	274
72	Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1348-1354.	2.8	109

#	ARTICLE	IF	CITATIONS
73	Improved adherence with PTH(1 α -84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2013, 24, 1503-1511.	3.1	12
74	Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. <i>Osteoporosis International</i> , 2013, 24, 329-338.	3.1	16
75	Risk Factors for Subtrochanteric and Diaphyseal Fractures: The Study of Osteoporotic Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 659-667.	3.6	53
76	The search for the optimal anabolic osteoporosis therapy. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2263-2265.	2.8	10
77	BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1319-1327.	2.8	50
78	A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2013, 10, 187-90.	1.0	4
79	Are Women with Thicker Cortices in the Femoral Shaft at Higher Risk of Subtrochanteric/Diaphyseal Fractures? The Study of Osteoporotic Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2414-2422.	3.6	23
80	Continuing Bisphosphonate Treatment for Osteoporosis – For Whom and for How Long?. <i>New England Journal of Medicine</i> , 2012, 366, 2051-2053.	27.0	249
81	Six Months of Parathyroid Hormone (1 α -84) Administered Concurrently Versus Sequentially with Monthly Ibandronate Over Two Years: The PTH and Ibandronate Combination Study (PICS) Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3522-3529.	3.6	43
82	The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 243-254.	2.8	552
83	Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 808-816.	2.8	169
84	Incidence and demography of femur fractures with and without atypical features. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 977-986.	2.8	147
85	Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1487-1493.	2.8	15
86	Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1627-1634.	2.8	109
87	Height loss in older women: Risk of hip fracture and mortality independent of vertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 153-159.	2.8	37
88	Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. <i>Osteoporosis International</i> , 2012, 23, 53-58.	3.1	30
89	Consistency of Bone Turnover Marker and Calcium Responses to Parathyroid Hormone (1 α -84) Therapy in Postmenopausal Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2011, 14, 68-73.	1.2	6
90	Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT. <i>Bone</i> , 2011, 48, 1298-1304.	2.9	16

#	ARTICLE	IF	CITATIONS
91	Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 12-18.	2.8	82
92	The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 683-688.	2.8	45
93	Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 984-992.	2.8	27
94	Effects of antiresorptive treatment on nonvertebral fracture outcomes. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2411-2418.	2.8	40
95	Teriparatide, Vitamin D, and Calcium Healed Bilateral Subtrochanteric Stress Fractures in a Postmenopausal Woman with a 13-Year History of Continuous Alendronate Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1627-1632.	3.6	109
96	Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2184.	7.4	561
97	Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1982-E1989.	3.6	95
98	Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 976-982.	2.8	241
99	Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 292-299.	2.6	121
100	Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. <i>New England Journal of Medicine</i> , 2010, 362, 1761-1771.	27.0	456
101	The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid. <i>Journal of the American Dental Association</i> , 2010, 141, 1365-1370.	1.5	99
102	Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. <i>Current Medical Research and Opinion</i> , 2009, 25, 921-928.	1.9	50
103	Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3215-3225.	3.6	96
104	Pentosidine and Increased Fracture Risk in Older Adults with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2380-2386.	3.6	281
105	Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 389-397.	2.8	143
106	Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1544-1551.	2.8	108
107	Defining a "Reference Population": No Easy Task. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1639-1639.	2.8	1
108	Proximal Femoral Structure and the Prediction of Hip Fracture in Men: A Large Prospective Study Using QCT. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1326-1333.	2.8	178

#	ARTICLE	IF	CITATIONS
109	Prevalent Vertebral Fractures in Black Women and White Women. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1458-1467.	2.8	90
110	Effects of PTH and Alendronate on Type I Collagen Isomerization in Postmenopausal Women With Osteoporosis: The PaTH Study. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1442-1448.	2.8	28
111	Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1974-1982.	2.8	191
112	Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2166-2172.	3.6	48
113	Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 378-379.	3.2	5
114	Alendronate and Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2007, 356, 1895-1896.	27.0	228
115	Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 942-947.	3.6	26
116	Use of Alendronate After 5 Years of Treatment—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1979.	7.4	1
117	Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 356, 1809-1822.	27.0	2,536
118	The effects of organic nitrates on osteoporosis: a randomized controlled trial [ISRCTN94484747]. <i>Trials</i> , 2006, 7, 10.	1.6	11
119	Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2927.	7.4	1,208
120	Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women ≥65 Years of Age: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 131-140.	2.8	120
121	Effect of Alendronate on the Age-Specific Incidence of Symptomatic Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 971-976.	2.8	86
122	Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 292-299.	2.8	163
123	Hip Fracture in Women without Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2787-2793.	3.6	542
124	Effect of Alendronate on Vertebral Fracture Risk in Women With Bone Mineral Density T Scores of -1.6 to -2.5 at the Femoral Neck: The Fracture Intervention Trial. <i>Mayo Clinic Proceedings</i> , 2005, 80, 343-349.	3.0	99
125	One Year of Alendronate after One Year of Parathyroid Hormone (1-84) for Osteoporosis. <i>New England Journal of Medicine</i> , 2005, 353, 555-565.	27.0	568
126	Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women 65 Years of Age: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 131-140.	2.8	167

#	ARTICLE	IF	CITATIONS
127	Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1259-1269.	2.8	238
128	Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1250-1258.	2.8	357
129	Vignettes in Osteoporosis: A Road Map to Successful Therapeutics. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 3-10.	2.8	7
130	The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2003, 349, 1207-1215.	27.0	1,133
131	Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial ¹ Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. <i>Bone</i> , 2003, 33, 293-300.	2.9	168
132	Pins and Plaster Arenâ€™t Enough: A Call for the Evaluation and Treatment of Patients with Osteoporotic Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3482-3486.	3.6	89
133	II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women. <i>Endocrine Reviews</i> , 2002, 23, 508-516.	20.1	396
134	Clinical Use of Bone Densitometry. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 1889.	7.4	664
135	Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. <i>American Journal of Medicine</i> , 2002, 112, 281-289.	1.5	679
136	Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 409-415.	2.6	55
137	Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1-10.	2.8	437
138	A Normative Reference Database Study for Pronosco X-posure Systemâ„¢. <i>Journal of Clinical Densitometry</i> , 2001, 4, 5-12.	1.2	57
139	An Assessment Tool for Predicting Fracture Risk in Postmenopausal Women. <i>Osteoporosis International</i> , 2001, 12, 519-528.	3.1	415
140	Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 241-249.	2.6	395
141	Inclusion of Older Women in Randomized Clinical Trials: Factors Associated with Taking Study Medication in the Fracture Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 1126-1131.	2.6	22
142	Epidemiology of Fractures and Assessment of Fracture Risk. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 439-454.	1.4	44
143	Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4118-4124.	3.6	877
144	Vertebral Fracture Prevalence Among Women Screened for the Fracture Intervention Trial and a Simple Clinical Tool to Screen for Undiagnosed Vertebral Fractures. <i>Mayo Clinic Proceedings</i> , 2000, 75, 888-896.	3.0	89

#	ARTICLE	IF	CITATIONS
145	Epidemiology of fractures and assessment of fracture risk. Clinics in Laboratory Medicine, 2000, 20, 439-53.	1.4	14
146	Defining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches. Journal of Bone and Mineral Research, 1999, 14, 90-101.	2.8	166
147	Prevalent Vertebral Deformities Predict Hip Fractures and New Vertebral Deformities but Not Wrist Fractures. Journal of Bone and Mineral Research, 1999, 14, 821-828.	2.8	693
148	Biochemical Markers of Bone Turnover and Prediction of Hip Bone Loss in Older Women: The Study of Osteoporotic Fractures. Journal of Bone and Mineral Research, 1999, 14, 1404-1410.	2.8	151
149	Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporosis International, 1999, 10, 259-264.	3.1	634
150	Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis and Rheumatism, 1999, 42, 1246-1254.	6.7	276
151	Hormonal Predictors of Bone Loss in Elderly Women: A Prospective Study. Journal of Bone and Mineral Research, 1998, 13, 1167-1174.	2.8	150
152	Correlates of Kyphosis in Older Women. Journal of the American Geriatrics Society, 1997, 45, 682-687.	2.6	122
153	Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, The, 1996, 348, 1535-1541.	13.7	3,496
154	Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. Journal of Bone and Mineral Research, 1996, 11, 984-996.	2.8	558
155	Insulin-like Growth Factor 1 and Functional Status in Healthy Older Men. Journal of the American Geriatrics Society, 1995, 43, 1350-1355.	2.6	92
156	Risk Factors for Hip Fracture in White Women. New England Journal of Medicine, 1995, 332, 767-773.	27.0	3,296
157	Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures. Journal of Bone and Mineral Research, 1995, 10, 890-902.	2.8	226
158	Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures. Journal of Bone and Mineral Research, 1995, 10, 1778-1787.	2.8	327
159	Simple measurement of femoral geometry predicts hip fracture: The study of osteoporotic fractures. Journal of Bone and Mineral Research, 1993, 8, 1211-1217.	2.8	606
160	Contribution of vertebral deformities to chronic back pain and disability. Journal of Bone and Mineral Research, 1992, 7, 449-456.	2.8	435
161	Age-related decrements in bone mineral density in women over 65. Journal of Bone and Mineral Research, 1992, 7, 625-632.	2.8	317
162	Axial and appendicular bone density predict fractures in older women. Journal of Bone and Mineral Research, 1992, 7, 633-638.	2.8	447

#	ARTICLE	IF	CITATIONS
163	Appendicular bone mineral and a woman's lifetime risk of hip fracture. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 639-646.	2.8	131
164	A new approach to defining normal vertebral dimensions. <i>Journal of Bone and Mineral Research</i> , 1991, 6, 883-892.	2.8	233
165	Prevalence of ABO Maternal-Infant Incompatibility in Asians, Blacks, Hispanics and Caucasians. <i>Vox Sanguinis</i> , 1988, 54, 181-183.	1.5	32
166	Recovery of Function After Hip Fracture The Role of Social Supports. <i>Journal of the American Geriatrics Society</i> , 1988, 36, 801-806.	2.6	154
167	A Distributed Data Processing System for a Multicenter Clinical Trial. <i>Drug Information Journal</i> , 1986, 20, 83-92.	0.5	5
168	Resources in Geriatric Drug Research. <i>Drug Information Journal</i> , 1985, 19, 421-427.	0.5	6